![Ryan Saadi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ryan Saadi
Nessuna posizione attualmente
Patrimonio netto: 96 M $ in data 31/05/2024
Posizioni attive di Ryan Saadi
Società | Posizione | Inizio | Fine |
---|
Storia della carriera di Ryan Saadi
Precedenti posizioni note di Ryan Saadi
Società | Posizione | Inizio | Fine |
---|---|---|---|
Tevogen Bio, Inc.
![]() Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Amministratore Delegato | 01/06/2020 | - |
Presidente | 01/06/2020 | - | |
Fondatore | 01/06/2020 | - |
Statistiche
Distribuzione geografica
Stati Uniti | 2 |
Posizioni
Chief Executive Officer | 2 |
Chairman | 2 |
Founder | 2 |
Settori
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Tevogen Bio, Inc.
![]() Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Health Technology |
- Borsa valori
- Insiders
- Ryan Saadi
- Esperienza